Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID06090903

Magnetic Resonance Imaging to Study Brain Tumor Biology and Decorin Expression in Patients With Resectable Glioblastoma

Led by Jonsson Comprehensive Cancer Center · Updated on 2025-11-10

50

Participants Needed

1

Research Sites

52 weeks

Total Duration

On this page

Sponsors

J

Jonsson Comprehensive Cancer Center

Lead Sponsor

N

National Cancer Institute (NCI)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are studying brain tumor biology in patients with glioblastoma that can be surgically removed. Glioblastoma is a type of malignant glioma with poor prognosis and limited treatment options. This trial focuses on using magnetic resonance imaging (MRI) to observe brain tumors and identify which patients may benefit from the drug bevacizumab by analyzing imaging biomarkers. Participants undergo a single MRI scan lasting about one hour before surgery. During surgery, patients will have 1 to 3 image-guided biopsies taken from tumor tissue planned for removal. Medical charts are also reviewed as part of the study procedures. The study aims to correlate MRI diffusion measurements with specific protein and genetic expressions within the tumors. Throughout the study, researchers will measure decorin (DCN) protein and genetic expression related to MRI diffusion values, as well as the incidence of certain cell types in tumors. Blood plasma levels of DCN protein will also be monitored up to five years. This long-term follow-up helps understand tumor characteristics linked to imaging features and the potential response to bevacizumab therapy.

CONDITIONS

Brief Title

Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients over 18 years of age
  • Newly diagnosed, suspected, or recurrent glioblastoma with tumors larger than 1.5 mL
  • Tumors planned for surgical removal
  • For recurrent glioblastoma, recurrence must be more than 3 months after radiation therapy according to guidelines
Not Eligible

You will not qualify if you...

  • Any contraindication to MRI, such as having a pacemaker or metal implants in the body
  • Patients under 18 years of age

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - Up to 1 day

Participants undergo one MRI scan lasting approximately 1 hour prior to surgery, along with image-guided biopsies within tumor tissue designated for removal and review of their medical chart.

1 visit (in-person)

Trial Site Locations

Total: 1 location

1

UCLA / Jonsson Comprehensive Cancer Center

Los Angeles, California, United States, 90095

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

SCREENING

Number of Arms

1

Similar Trials

A Phase 1 Safety and Dose Finding Study of 131I-TLX101 Plus ...

Neoplastic Disease

Actively Recruiting

6 locations

Combined (Neo-)Adjuvant Intravenous and Intracranial Ipilimu...

Recurrent Glioblastoma

Actively Recruiting

1 location

A Phase II, Multi-site, Open-label Trial Evaluating the Safe...

Recurrent Glioblastoma

Actively Recruiting

6 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here